AVRO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide...

Stats
今日成交量	202 091
平均成交量	220 879
市值	54.73M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-0.360 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	4.52
ATR14	$0.00500 (0.41%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-01	Golipour Azadeh	Sell	37 334	Restricted Stock Unit
2024-02-01	Golipour Azadeh	Buy	37 334	Common Stock
2024-02-05	Golipour Azadeh	Sell	12 232	Common Stock
2024-02-01	Ridha Essra	Sell	32 834	Restricted Stock Unit
2024-02-01	Ridha Essra	Buy	32 834	Common Stock

INSIDER POWER
54.75
Last 100 transactions
Buy: 6 327 240 \| Sell: 1 294 974

音量相关性

長: -0.33 (neutral)

短: -0.67 (moderate negative)

Signal:(45.204) Neutral

AVROBIO Inc 相关性

10 最正相关
TLS	0.933
MBIN	0.909
HUBG	0.893
ALLK	0.892
PMBC	0.888
BNGO	0.885
NBTB	0.884
ITOS	0.876
ATNX	0.873
CLOV	0.873

10 最负相关
AAON	-0.865
DPCS	-0.861
GRPH	-0.851
BNIXU	-0.845
KVSC	-0.845
CINC	-0.844
SGEN	-0.842
IPAR	-0.841
BCOR	-0.839
PRTC	-0.829

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

AVROBIO Inc 相关性 - 货币/商品

0.41
( neutral )

0.38
( neutral )

0.00
( neutral )

0.32
( neutral )

AVROBIO Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-617 000 (0.00 %)
EPS:	$0.270

FY	2023
营收:	$0
毛利润:	$-617 000 (0.00 %)
EPS:	$0.270

FY	2022
营收:	$0
毛利润:	$-4.17M (0.00 %)
EPS:	$-2.42

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.78

Financial Reports:

No articles found.

AVROBIO Inc

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

实时更新： AVROBIO Inc [AVRO]

Upcoming Earnings Alert